Weight loss drugs for cats? A biopharma company arms itself with a novel approach to shrinking pets. Okava Pharmaceuticals, based in San Francisco, is poised to unveil on Tuesday a GLP-1–based weight-management trial for cats. The MEOW-1 study will test OKV-119, a compact implant that delivers GLP-1 steadily for up to six months.
Okava asserts that MEOW-1 marks the first-ever weight-loss study in household cats using this method. The trial plans to enroll up to 50 felines who will receive the implant, with weight assessments conducted at the three-month mark while monitoring continues for a full six months, according to Okava’s CEO Michael Klotsman.
Klotsman indicated the aim is to file for FDA approval sometime between 2027 and 2028, with a projected out-of-pocket cost to owners around $100 per month.
Weight management is framed by Okava as having transformative health benefits for cats. The company argues that weight reduction is the only proven way to extend a cat’s lifespan, noting leaner cats reach lower diabetes risk thresholds and experience relief from weight-related joint pain.
A notable statistic cited by the company is that more than half of domestic cats are overweight or clinically obese, underscoring the weight crisis within felines.
For the study, Okava will use exenatide as the GLP-1 component, a different agent than what humans typically use in popular weight-loss drugs. (Ozempic employs semaglutide and Mounjaro uses tirzepatide.)
Okava claims several pet-specific advantages over traditional diet-and-exercise regimens, including reduced diabetes risk through improved glucose metabolism, decreased osteoarthritic pain and inflammation, enhanced cardiovascular function, and better insulin sensitivity.
Preliminary studies reportedly indicate the implant and GLP-1 therapy are safe and beneficial for pets. Beyond cats, Okava plans to study dogs in a subsequent trial.
The company asserts that the medicine acts similarly in pets as it does in humans. Pet owners could expect noticeable behavioral shifts: less food motivation and begging, reduced scavenging, and better portion control as weight declines. They also anticipate increased activity and energy as metabolic health improves.
GLP-1 therapies work by promoting insulin production and lowering blood sugar levels. They slow gastric emptying and suppress appetite, driving weight loss. Variants of GLP-1 drugs have surged in popularity in human medicine as injectable weight-loss treatments.
